Staff members (REF1a/c)
1 - Clinical Medicine
Cardiff University
- I - Institute of Infection and Immunity
- C - Institute of Cancer and Genetics
- I - Institute of Infection and Immunity
- C - Institute of Cancer and Genetics
- C - Institute of Cancer and Genetics
- C - Institute of Cancer and Genetics
- I - Institute of Infection and Immunity
- C - Institute of Cancer and Genetics
- C - Institute of Cancer and Genetics
- I - Institute of Infection and Immunity
- I - Institute of Infection and Immunity
- I - Institute of Infection and Immunity
- C - Institute of Cancer and Genetics
- C - Institute of Cancer and Genetics
- C - Institute of Cancer and Genetics
- I - Institute of Infection and Immunity
- I - Institute of Infection and Immunity
- C - Institute of Cancer and Genetics
- C - Institute of Cancer and Genetics
Professor Fegan is a full-time employee of Cardiff and Vale University Health Board with ring-fenced time for research in his job plan. He also holds an Honorary Chair in Haematology conferred by Cardiff University by virtue of his outstanding contribution to leukaemia research. His particular research interest is in chronic lymphocytic leukaemia (CLL). The Cardiff CLL Research Group is co-led by Professor Fegan and is currently comprised of 4 principal investigators, 5 postdoctoral scientists, one Clinical Fellow and six PhD students. Professor Fegan is being returned in UOA1 (clinical medicine) as his research is clearly focussed in this unit of assessment as it encompasses basic cancer cell biology, biomarker discovery and clinical trials.
- C - Institute of Cancer and Genetics
Dr Fry works full time in clinical genetics with Cardiff and Vale University Health Board. He holds a Walport Clinical Lectureship. His research is in the clinical and molecular genetics of disease. His academic supervisor is Professor Julian Sampson (Cardiff University) and he is currently working with Prof Dr Pilz (Cardiff and Vale UHB) on congenital brain malformation and is developing research into the genetic basis of very early onset epilepsies. His intention is to develop a career in academic clinical genetics. Dr Fry is being returned in UOA1 (clinical medicine) reflecting the focus of his research on the genetic mechanisms of this group of congenital and early onset disorders.
- I - Institute of Infection and Immunity
- I - Institute of Infection and Immunity
- I - Institute of Infection and Immunity
- C - Institute of Cancer and Genetics
- I - Institute of Infection and Immunity
- I - Institute of Infection and Immunity
- I - Institute of Infection and Immunity
- I - Institute of Infection and Immunity
- I - Institute of Infection and Immunity
- C - Institute of Cancer and Genetics
- I - Institute of Infection and Immunity
- C - Institute of Cancer and Genetics
- C - Institute of Cancer and Genetics
- I - Institute of Infection and Immunity
- I - Institute of Infection and Immunity
- C - Institute of Cancer and Genetics
- C - Institute of Cancer and Genetics
- I - Institute of Infection and Immunity
- C - Institute of Cancer and Genetics
- C - Institute of Cancer and Genetics
- I - Institute of Infection and Immunity
- I - Institute of Infection and Immunity
- C - Institute of Cancer and Genetics
- I - Institute of Infection and Immunity
- I - Institute of Infection and Immunity
- C - Institute of Cancer and Genetics
- C - Institute of Cancer and Genetics
- C - Institute of Cancer and Genetics
- I - Institute of Infection and Immunity
- I - Institute of Infection and Immunity